Repository logo
 
Publication

Anti-myopia spectacles: the standard of care in the future?

2024-02Journal article Embargoed access
Simple item page
dc.contributor.authorLança, Carla
dc.contributor.authorPan, Chen-Wei
dc.contributor.authorGrzybowski, Andrzej
dc.date.accessioned2024-05-06T09:16:57Z
dc.date.embargo2026-05-06
dc.date.issued2024-02
dc.description.abstractReports of myopia increases across the world show an expanding growing public health problem. Myopia prevalence is exceptionally high in some continents, especially in Asia and particularly east Asian countries, but was also reported to have increased in other continents, such as North America and Europe, although there is considerable variation between geographic areas and racial groups in the myopia burden. The presence of myopia, especially high myopia, increases the risk of development of pathologic myopia and visual impairment. The peak incidence of myopia occurs in childhood, but the associated blinding ocular complications develop later during adulthood. Children with an increased risk of visual impairment due to pathologic myopia often have a longer duration of the disease, longer axial length (AL), and thinner choroid. Thus, myopia control therapies should be implemented early to avoid the development of high myopia, as the early age of myopia onset plays a fundamental role in myopia progression, with about 50% of children with myopia onset at 7 or 8 years of age developing high myopia in adulthood, if left untreated. Increased prevalence of high myopia related to AL elongation is likely to result in higher rates of myopic macular degeneration (MMD). At present, we do not know if treating myopic progression will avoid the development of MMD. However, it seems logical to slow AL elongation to prevent severe disease and complications associated with pathologic myopia. Consequently, controlling myopia progression has become one of the highest priorities for eye care professionals all over the world.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationLança C, Pan CW, Grzybowski A. Anti-myopia spectacles: the standard of care in the future? Am J Ophthalmol. 2024;263:xi-xiii.pt_PT
dc.identifier.doi10.1016/j.ajo.2024.02.027pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/17427
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0002939424000837pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectOphthalmologypt_PT
dc.subjectMyopiapt_PT
dc.subjectPublic healthpt_PT
dc.titleAnti-myopia spectacles: the standard of care in the future?pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPagexiiipt_PT
oaire.citation.startPagexipt_PT
oaire.citation.titleAmerican Journal of Ophthalmologypt_PT
oaire.citation.volume263pt_PT
person.familyNameLança
person.givenNameCarla
person.identifier.ciencia-id601A-6412-BF2F
person.identifier.orcid0000-0001-9918-787X
rcaap.rightsembargoedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication0320b455-ee19-4670-8bf2-10dce9de1bec
relation.isAuthorOfPublication.latestForDiscovery0320b455-ee19-4670-8bf2-10dce9de1bec

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Anti-myopia spectacles_the standard of care in the future.pdf
Size:
262.54 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos